Pharma Whitepapers

Citeline Study Feasibility

Minimizing Luck in Study Feasibility

This informative whitepaper introduces you to best practices in study feasibility, which laid the groundwork for our new predictive analytic that is launching soon, Citeline Study Feasibility.  Our industry-leading technology will deliver advanced insight to improve your clinical trial decisions, fast-track enrollment and optimize cycle times – all with less effort.

Minimizing Luck in Study Feasibility Part 2

Study feasibility is a fundamental contributor to the overall success of a clinical development program. However, selecting the right countries, sites and investigators and starting up as quickly as possible remains a challenge, leading to greatly variable performance and inaccurate predictions for important trial milestones.

Biomedtracker

2020 Deal-Making Roundup

Against a backdrop of unprecedented disruption, the biopharma and medtech industries reached incredible heights for deal-making activity during 2020.

Citeline, Trialtrove

2020 Completed Trials A Bumpy Road for Industry Sponsored Clinical Studies

Over the past five years, our analysis of completed trials consistently observed growth trends.

Pharmaprojects, Citeline

Pharma R&D Annual Review & NAS Supplement 2021

Our world was disrupted at warp speed during 2020. Are you ready to gain a deeper understanding of the year that changed our perceptions of possible? 

Biomedtracker

Biopharma Partnering and Financing Trends, H1 2020 Whitepaper

Get an inside view into the trends powering COVID-era deal making in the life sciences with your free copy of “Biopharma Partnering and Financing Trends, H1 2020”. Informa Pharma Intelligence takes you inside the forces shaping the industry

Biomedtracker

2021 Clinical Development Success Rates

This is both an updated study of clinical drug development success rates from our 2016 report, and an expansion into the drivers of success with the addition of machine learning modeling to analyze the predictive factors contributing to drug development.

Pharma Brand Awareness

Developing high quality content for the pharma industry

To reach today’s Pharma decision makers, you must provide the right high-quality content to help them make educated purchasing decisions – and become loyal customers.

Citeline

Depression New Insights Shifting the Treatment Paradigm Whitepaper

Depression affects approximately 1 in 6 Americans, with 10 – 30% of depression patients becoming treatment-resistant. Find out what the pipeline looks like for depression and what the emerging strategies in this area are. This data-packed whitepaper from Informa Pharma Intelligence can now be downloaded – free.